Production (Stage)
Avalo Therapeutics, Inc.
AVTX
$3.75
-$0.16-4.09%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 151.10% | -11.37% | 76.02% | -46.25% | -383.32% |
| Total Depreciation and Amortization | 69.81% | 6.96% | -4.00% | 5.59% | 20.45% |
| Total Amortization of Deferred Charges | -- | -- | -100.00% | -19.47% | 6.41% |
| Total Other Non-Cash Items | -199.96% | -215.64% | -392.70% | 7.13% | 1,250.91% |
| Change in Net Operating Assets | 74.97% | 49.05% | 57.86% | -37.46% | -390.98% |
| Cash from Operations | -94.97% | -59.90% | -15.46% | -66.32% | -29.39% |
| Capital Expenditure | -- | -- | 100.00% | 100.00% | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -100.00% | -100.00% | -100.00% |
| Cash Acquisitions | -100.00% | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -100.00% | 367.67% | 367.67% | 306.98% | 256.14% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 100.00% | -154.07% | -43.48% |
| Issuance of Common Stock | -53.13% | 299.84% | 149.37% | 592.99% | 969.38% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 68.54% | -- | -- | -- | -- |
| Cash from Financing | -43.93% | 602.22% | 330.45% | 723.65% | 12,708.41% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -84.02% | 2,303.24% | 1,144.86% | 1,829.65% | 526.34% |